| Field | Specification |
|---|---|
| Target | |
| Alternative names | Steroid 17-alpha-hydroxylase/17,20 lyase;1.14.14.19 ;17-alpha-hydroxyprogesterone aldolase;4.1.2.30 ;CYPXVII;Cytochrome P450 17A1;Cytochrome P450-C17;Cytochrome P450c17;Steroid 17-alpha-monooxygenase;CYP17A1;CYP17, S17AH; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human CYP17A1, different from the related mouse and rat sequences by ten amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody detects steroid 17-alpha-hydroxylase/17,20 lyase (gene CYP17A1) in human and rat samples and is validated for flow cytometry, IHC and Western blot. The predicted molecular weight is 57.4 kDa, and the supplier reports an observed band at about 57 kDa.
CYP17A1 is a cytochrome P450 of the endoplasmic reticulum with two activities: 17α-hydroxylase, needed for cortisol synthesis, and 17,20-lyase, needed for androgen synthesis. It sits at a branch point of adrenal and gonadal steroidogenesis and is the target of the prostate cancer drug abiraterone, so it is widely studied in endocrine and cancer research.
| Target | Steroid 17-alpha-hydroxylase/17,20 lyase (gene CYP17A1; UniProt P05093, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.01 mg NaN3 |
| Calculated MW | 57.4 kDa |
| Observed MW | 57 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.1–0.5 µg/mL (Human, Rat) |
|---|---|
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Flow cytometry (fixed cells) | 1–3 µg/1×106 cells (Human) |
Samples with a confirmed band (WB): human SH-SY5Y cells, human HepG2 cells, human HeLa cells, human Jurkat cells, rat testis tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human testis tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with a confirmed signal (flow cytometry): U87 cells.
Immunogen
Synthetic peptide from the C-terminal region of human CYP17A1. It differs from the mouse and rat sequences at ten residues.
Reactivity Notes
The supplier lists reactivity with human and rat. UniProt places steroid 17-alpha-hydroxylase/17,20 lyase in the endoplasmic reticulum membrane and microsome membrane. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
